Cerebrovascular comorbidity, high blood levels of C-reactive protein and D-dimer are associated with disease outcomes in COVID-19 patients

Foad Alzoughool\textsuperscript{a,}\textsuperscript{,*}, Lo’ai Alanagreh\textsuperscript{b}, Suhad Abumweis\textsuperscript{b,}\textsuperscript{,}\textsuperscript{c} and Manar Atouma\textsuperscript{a}

\textsuperscript{a}Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa, Jordan
\textsuperscript{b}Department of Clinical Nutrition and Dietetics, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa, Jordan
\textsuperscript{c}College of Pharmacy, AL Ain University, Abu Dhabi, United Arab Emirates

Abstract. The emerging coronavirus disease (COVID-19) swept the world, affecting more than 200 countries and territories. As of August 22, 2020, the pandemic infected more than 23,329,752 including 807,054 patients who have died. Although the main clinical features of the pandemic disease are respiratory, cerebrovascular comorbidities emerged as one of the leading causes of death associated with COVID-19. Different case reports have indicated that C-reactive protein (CRP) and D-dimer (pro-inflammatory biomarkers) were elevated in COVID-19 patients, which can significantly increase the risk of ischemic stroke. Available data on cerebrovascular complications in COVID-19 patients were collected and a meta-analysis was designed and carried out to evaluate the risk of severity and mortality associated with high levels of CRP and D-dimer levels in COVID-19 patients. In addition, we aimed to describe the overall event rate of pre-existing cerebrovascular disease in COVID-19 patients. In our analysis, 5,614 cases have been studied, out of these patients 164 cases have developed cerebrovascular comorbidities. Cerebrovascular comorbidity increased the risk of disease severity (odd ratio = 4.4; 95%CI: 1.48 to 12.84) and mortality (odd ratio = 7.0; 95%CI: 2.56 to 18.99). Statistical analyses showed that CRP and D-dimer serum levels were elevated by six-folds in the severe cases of COVID-19 patients. This significant increase in these two proteins levels can serve as a vital indicator for COVID-19 patients who are at increased risk of severe COVID-19 cerebrovascular complications, such as stroke.

Keywords: Cerebrovascular disease, COVID-19, stroke, C-reactive protein, D-dimer

1. Introduction

The novel coronavirus disease (COVID-19) was first identified in patients with severe respiratory illness in Wuhan, China, in December of 2019. The causative agent was a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1–4]. The worrisome features of COVID-19 are its ability to spread readily and its propensity to cause severe disease in older adults and patients with pre-existed health conditions. These cases are often associated with a high risk of cerebrovascular diseases, cardiovascular disease, hypertension, diabetes, and even death [5, 6].
Cerebrovascular and cardiovascular comorbidities are among the most common cause of death associated with COVID-19 [6]. Stroke incidence and cerebrovascular disease have been reported in 5% and 5.7% of COVID-19 patients, respectively [7]. However, the thrombotic changes are generalized and occur in all regions of the body - not only in the brain), as it was demonstrated by previous studies like thromboses in the lung [8], kidney infarctions [9], as well as overt intravascular disseminated coagulation [10]. The pro-inflammatory biomarkers were elevated significantly due to the COVID-19 infection. Increased levels of pro-inflammatory markers are known to increase the risk of ischemic stroke, particularly in the elderly and chronically ill patients [11]. Although there are no supporting evidences to the role of inflammation in stroke pathogenesis, it was suggested that inflammation might cause a stroke by several mechanisms such as genetic susceptibility, presence of traditional risk factors (hypertension, diabetes mellitus, smoking, and cardiac diseases), and infectious diseases [12].

C-reactive protein (CRP) is a protein synthesized in the liver as an acute-phase reactant in response to an inflammation; and it plays a significant role in the pathophysiological process of stroke [13]. D-dimer is a small protein fragment produced by fibrinolysis’s degradation of the blood clot that might be used to diagnose thrombosis by measuring its concentration [14]. The elevation of circulated D-dimer plasma concentration indicates activation in blood coagulation thrombin formation, particularly in the intra-arterial that is associated with ischemia [15]. Several studies also have reported associations between ischemic cerebrovascular disease and inflammatory indexes such as CRP and fibrinogen [16, 17]. In addition, other studies have reported an increase in stroke severity with elevated D-dimer concentration [18, 19]. The associations between serum levels of CRP and D-dimer and stroke suggest a relation between the inflammatory process and the risk of stroke. Accordingly, this meta-analysis study was performed (i) to investigate overall event rate of pre-existing cerebrovascular disease in patients with COVID-19, (ii) to find the association between pre-existing cerebrovascular diseases and disease severity and mortality in COVID-19 patients; and (iii) to evaluate the risk of severity and mortality associated with high levels of CRP and D-dimer levels in COVID patients.

2. Methods

2.1. Data search

Three databases including PubMed, Science Direct, and Scopus were searched between 1 January 2020 and 30 May 2020 to find studies that reported pre-existing cerebrovascular diseases, CRP levels, or D-dimer levels in COVID-19 patients. The following combined keywords were used for searching the databases: CRP, Stroke, COVID-19, D-dimer, and SARS-CoV-2. Besides, the lists of references of all relevant studies were also manually checked to identify further studies.

2.2. Study selection

The language was limited to English. Studies were selected if they had case series designs and provided adequate details on clinical symptoms and laboratory results, particularly CRP and D-dimer protein levels.

2.3. Data abstraction

For studies that met the inclusion criteria, the following data were extracted from each included study using a standardized form: the surname of the first author; the design of the study; number, age and sex of patients; ratios of clinical and laboratory characteristics of interest; and data relevant
to cerebrovascular comorbidities factor. All concentration units of CRP or D-dimer protein levels in all studies were justified and converted to unify unit each, mg/L, and ng/ml, respectively. Values 10 mg/L and more identified high levels of CRP, and the high level of D-dimer were identified by values ≥0.5 mg/L. The severity of the disease validation, as reported in the included studies, was determined if patients needed to be admitted to the intensive care unit, needed vital life support, required mechanical ventilation, or death. Data extraction was carried out by FA and double-checked by MA.

2.4. Quality assessment

The methodological quality was assessed with the National Institutes of Health Joanna Briggs Institute (JBI) quality assessment tool for case series studies [20]. The quality of case series studies was investigated by one reviewer (SA). Quality checklist of the JBI tool is based on ten criteria including: inclusion criteria; the method of measurement of the condition, the method of measurement of the outcomes; whether inclusion of case was consecutive or not; the completeness of a case series; reporting of relevant participant’s demographics; reporting of clinical information of the participants; description of the clinical condition post-intervention; reporting of the presenting site(s)/clinic(s) demographic information; and consideration of statistical analysis.

2.5. Quantitative data synthesis and analysis

Random-effects meta-analysis was used to calculate pooled crude prevalence rate, with 95% confidence intervals of high levels of CRP and D-dimer measures, besides cerebrovascular comorbidities of COVID-19 patients. A pooled analysis was carried out to assess the odds ratio (OR) and 95% confidence interval (CI) of high levels of CRP and D-dimer, as well as pre-existing cerebrovascular disease in COVID-19 patients with or without severe disease and in non-survivors versus survivors. All statistical analyses were carried out by Comprehensive Meta-Analysis V2 (Biostat, USA). A p-value of <0.05 was considered statistically significant. Heterogeneity in study results was tested by using the I² statistic (p-value of <0.1). I² provides an estimate of the percentage of variation in study results that is explained by between-study heterogeneity rather than sampling error. An I² value >50% indicates considerable heterogeneity [21]. The presence of publication bias was examined for using a funnel plot.

3. Results

A total of 851 articles were identified from the three databases examined and other sources. The initial searched included 683 articles; after excluding duplicated or overlapping articles and removing reviews and editorials, a total number of 168 publications could be initially identified. A hundred Fifty-three studies were excluded because they did not have a data about pre-existing cerebrovascular disease in COVID patients or no data about the levels of CRP and D-dimer protein among patients who positively diagnosed with COVID-19. For the quantitative assessment of our study, sixteen studies were included in the meta-analysis that reported either the event rate of pre-existing cerebrovascular disease, high CRP levels, and/or high D-dimer levels (Fig. 1).

Table 1 shows the details and the characteristics of the studies used in the pooled-analysis. Studies included in the meta-analysis were conducted mostly in China and published between 1 January 2020 and 30 May 2020. The sixteen included studies examined 5,611 cerebrovascular patients’ records. These 16 studies were based on data collected worldwide with clinical symptoms observed in patients with COVID-19, with a clear explanation of eligibility criteria and diagnosis criteria.
The pooled event rate from 16 studies of cerebrovascular comorbidity in COVID-19 patients revealed a prevalence of 4 % (95%CI: 2.8 to 5.9%), as shown in Fig. 2. The associations of cerebrovascular comorbidity with disease outcomes are shown in Figs. 3 and 4. Cerebrovascular comorbidity increased the risk of disease severity more than four folds (OR = 4.4; 95%CI: 1.48 to 12.84) (Fig. 3). The cerebrovascular disease comorbidity was associated with about seven times the risk of non-surviving COVID-19 (odd ratio = 7.0; 95%CI: 2.56 to 18.99) (Fig. 4).
Table 1
Pre-existing cerebrovascular and high levels of CRP and D-dimer distribution in the included studies of patients with COVID-19

<table>
<thead>
<tr>
<th>Country</th>
<th>Condition</th>
<th>Sample size</th>
<th>Events (n)</th>
<th>Non-events (n)</th>
<th>Severe cases ratio</th>
<th>Non-sever cases ratio</th>
<th>Non-survivors</th>
<th>Survivors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hu L, et al. [38]</td>
<td>USA Cerebrovascular</td>
<td>323</td>
<td>7</td>
<td>316</td>
<td>3/172</td>
<td>4/151</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhang J, et al. [40]</td>
<td>China Cerebrovascular</td>
<td>140</td>
<td>3</td>
<td>125</td>
<td>2/58</td>
<td>1/82</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Du Y, et al. [51]</td>
<td>China Cerebrovascular</td>
<td>85</td>
<td>7</td>
<td>78</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lei S, et al. [52]</td>
<td>China Cerebrovascular</td>
<td>34</td>
<td>2</td>
<td>32</td>
<td>2/15</td>
<td>0/19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Qin C, et al. [28]</td>
<td>China Cerebrovascular</td>
<td>452</td>
<td>11</td>
<td>441</td>
<td>8/286</td>
<td>3/166</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lagi F, et al. [31]</td>
<td>Italy Cerebrovascular</td>
<td>84</td>
<td>2</td>
<td>82</td>
<td>0/16</td>
<td>2/68</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yang X, et al. [34]</td>
<td>China Cerebrovascular</td>
<td>52</td>
<td>7</td>
<td>45</td>
<td>7/32</td>
<td>0/20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yan Y, et al. [36]</td>
<td>China Cerebrovascular</td>
<td>193</td>
<td>8</td>
<td>185</td>
<td>8/108</td>
<td>0/85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guan WJ, et al. [27]</td>
<td>China Cerebrovascular</td>
<td>1590</td>
<td>30</td>
<td>1560</td>
<td>7/30</td>
<td>23/1560</td>
<td>6/30</td>
<td>24/1560</td>
</tr>
<tr>
<td>Chen T [33]</td>
<td>China Cerebrovascular</td>
<td>274</td>
<td>4</td>
<td>270</td>
<td></td>
<td>4.0/113</td>
<td>0/161</td>
<td></td>
</tr>
<tr>
<td>Guan W et al. [5]</td>
<td>China CRP</td>
<td>793</td>
<td>481</td>
<td>312</td>
<td>110/135</td>
<td>371/658</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huang Y, et al. [39]</td>
<td>China CRP</td>
<td>208</td>
<td>72</td>
<td>136</td>
<td>58/89</td>
<td>14/119</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhang J, et al. [40]</td>
<td>China CRP</td>
<td>81</td>
<td>35</td>
<td>46</td>
<td>23/38</td>
<td>12/43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhou F, et al. [41]</td>
<td>China D-dimer</td>
<td>172</td>
<td>117</td>
<td>55</td>
<td></td>
<td>50/54</td>
<td>67/118</td>
<td></td>
</tr>
</tbody>
</table>
In the pooled analysis, high levels of D-dimer and CRP were found to be significantly associated with about six-folds increased risk of COVID severity (odds ratio = 5.90; 95%CI: 1.49 to 23.24 and 5.70; 95%CI: 1.93 to 16.79 respectively), as shown in both Figs. 5 and 6.
Fig. 6. The pooled analysis of the association of high levels of D-dimer with COVID-19 severity in adult patients.

A random-effect model was used for all pooled analyses as a significant heterogeneity was observed across all included studies.

As shown Fig. 7 that evaluates publication bias using a funnel plot based on the event rate of cerebrovascular comorbidity, a visual symmetry indicates the absence of publication bias. Also, the Egger’s test revealed no significant publication bias (Egger’s test: \( p = 0.16593 \))

Table 2 shows the methodological quality of all studies included in the meta-analyses. Defined inclusion criteria were not there in 13 studies. The measurement method of the condition was reported in all studies, whereas the method of measurement of the outcomes was published in the majority of studies. Whether cases were recruited consecutively is not clear in five studies and two studies. Similarly, the complete inclusion of participants is not explicit in the majority of the included studies. On the other hand, all studies reported relevant participant demographics, clinical information of the participants; description of the clinical condition post-intervention; the presenting site(s)/clinic(s) demographic information; and the statistical analysis.
Table 2
The methodological quality of the included case series studies in the meta-analyses using the Joanna Briggs Institute critical appraisal tools

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Were there clear criteria for inclusion in the case series?</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Was the condition measured in a standard, reliable way for all participants included in the case series?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Were valid methods used for identification of the condition for all participants included in the case series?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Clear</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Did the case series have consecutive inclusion of participants?</td>
<td>Not clear</td>
<td>Not clear</td>
<td>Yes</td>
<td>Yes</td>
<td>Not clear</td>
<td>Not clear</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Not clear</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Did the case series have complete inclusion of participants?</td>
<td>Not clear</td>
<td>Not clear</td>
<td>Not clear</td>
<td>No</td>
<td>Yes</td>
<td>Not clear</td>
<td>Not clear</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Not clear</td>
<td>Not clear</td>
<td>Not clear</td>
<td>Not clear</td>
<td>Not clear</td>
</tr>
<tr>
<td>Was there clear reporting of the demographics of the participants in the study?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Was there clear reporting of clinical information of the participants?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Were the outcomes or follow up results of cases clearly reported?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Was there clear reporting of the presenting site(s)/clinic(s) demographic information?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Was statistical analysis appropriate?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>
4. Discussion

In the present meta-analysis, we have explored 16 independent studies reported cerebrovascular disease as a comorbid factor on about 5,611 confirmed COVID-19 patients distributed across many countries. Results showed that the pre-existing cerebrovascular disease, as well as high levels of D-dimer or CRP, are associated with severe outcomes in COVID-19 patients.

Generally, previous studies have been shown the association between CRP, D-dimer and stroke [49,50]. A dose-response meta-analysis study about the association between CRP level and the risk of ischemic stroke showed that high level of CRP is related to increase the risk of ischemic strokes. Moreover, the result also showed that risk was significantly reduced by controlling the CRP at a low level [42]. Our results were also supported by an Italian study that was investigating the relationship between the serum concentration level of CRP and prognosis after ischemic stroke [43], the study’s findings suggested that post-stroke patients with CRP levels higher than 15 mg/L have a worse prognosis and a higher risk of subsequent cardiovascular complications which might lead to death [43]. An additional meta-analysis study demonstrated that increased CRP level was independently linked with an elevated 2.07-fold risk of mortality in patients with acute ischemic stroke [44]. Among all studies included in this meta-analysis, the highest CRP cut-off value was 31.2 mg/l [45]. Moreover, In a study that included 3653 patients with first-ever ischemic stroke, the elevated plasma CRP (>4.70 mg/l) is independently related to adverse clinical outcomes after acute ischemic stroke [46]. In a case-control study, it was reported that the concentration of CRP in mg/l among 600 patients with ischemic stroke was 3.48 (1.52–9.42), the level of CRP in mg/l among 73 patients with the large-vessel disease (LDV) was 4.66 (1.79–13.9), the concentration of CRP in mg/l among 124 patients with the small-vessel disease (SDV) was 3.08 (1.52–5.79), the level of CRP in mg/l among 98 patients with the cardio-embolic stroke (CE) was 7.07 (2.39–17.8). The study reported significant differences in CRP levels between different ischemic stroke etiological subtypes. However, the maximum level of CRP measured was 17.8 mg/l [47]. In comparison with our study, all these studies showed mildly increased CRP levels in patients with ischemic stroke. Our pooled analysis indicated that CRP levels were associated with about six-folds increased risk of COVID severity, however, due to insufficient reporting of data, we could not analysis direct association of pro-inflammatory markers in patients with COVID-19 who developed stroke compared to those who did not. Future studies should look at the suggestion that COVID-19 disease massively increase the level of CRP that could be an excellent candidate to be a biomarker for stroke in COVID-19 patients.

High levels of D-dimer is also prevalent in COVID-19 patients. Consistent with our study, a case-control study performed on 240 Chinese patients with acute ischemic stroke (AIS) showed that plasma D-dimer levels increased with increasing stroke severity, besides it significantly increased in AIS patients compared to healthy controls [18]. The results showed that the D-dimer levels in AIS patients range from 280–2110 ng/ml compared to healthy controls that range from 170–740 ng/ml [18]. Moreover, the mean D-dimer level at the admission of 59 acute ischemic stroke patients was 626 mg/ml (range, 77–4,752 mg/ml), and the mean level measured after seven days of treatment was 238.3 mg/ml (range, 50–924 mg/ml), besides that D-dimer level has reported positively correlated with infarction volume and suggested to be used to predict infarction-volume [48]. Another meta-analysis study which investigated the association between D-dimer level and the risk of stroke included seven prospective observational studies with a total of 22,207 patients and three case-control studies with 2,248 patients; the study showed a significantly higher risk of stroke associated with the increased level of D-dimer [19] which support our results. Our pooled analysis indicated that D-dimer levels were associated with almost six-fold increased risk of COVID-19 severity, which also suggests that COVID-19 disease with stroke enormous increased the level of D-dimer protein suggesting that D-dimer may be used to screen patients at risk of stroke in COVID-19 patients.
Systematic reviews and meta-analyses on case series studies with low risk of bias are essential to describe and understand new diseases, including COVID-19. A rational analysis of our analysis is the absence of publication bias, meaning that all relevant studies have been identified. A common limitation of the studies included in our analysis is that it was not clear what the eligibility criteria were and if participants’ selection was consecutive and complete. Other biases in the included studies are less likely since all studies reported adequately addresses other items in the JBI checklist.

5. Conclusion

CRP and D-dimer serum levels are prevalent in patients who are positively diagnosed Covid-19 and may put them at increased risk of stroke development. Patients with pre-existing cerebrovascular disease are at increased risk of severe COVID-19 outcomes as well as mortality. High levels of D-dimer and CRP are associated with a higher risk of severe outcomes of COVID-19, suggesting that they may serve as biomarkers to identify patients at risk of undesirable outcomes. Nevertheless, prospective cohort studies are needed to confirm such associations.

Conflicts of interest

The authors declare no conflict of interest.

Funding

This research received no external funding.

References


